Icosabutate - NorthSea Therapeutics

Drug Profile

Icosabutate - NorthSea Therapeutics

Alternative Names: PRC-4016

Latest Information Update: 16 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pronova BioPharma
  • Class Antihyperlipidaemics; Omega 3 fatty acids; Unsaturated fatty acids
  • Mechanism of Action Cholesterol ester transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dyslipidaemias; Hypertriglyceridaemia
  • Phase I Hypercholesterolaemia

Most Recent Events

  • 12 Apr 2018 Pharmacodynamics data from a preclinical trial in Non-alcoholic steatohepatitis released by NorthSea Therapeutics
  • 12 Dec 2017 NorthSea Therapeutics plans a phase IIb trial for Non-alcoholic steatohepatitis by the end of 2018
  • 12 Dec 2017 Icosabutate licensed to NorthSea Therapeutics before December 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top